NCT07428889

Brief Summary

The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at P25-P50 for not_applicable

Timeline
0mo left

Started Feb 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress91%
Feb 2026Jun 2026

First Submitted

Initial submission to the registry

February 2, 2026

Completed
15 days until next milestone

Study Start

First participant enrolled

February 17, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 24, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Last Updated

April 13, 2026

Status Verified

February 1, 2026

Enrollment Period

3 months

First QC Date

February 2, 2026

Last Update Submit

April 9, 2026

Conditions

Healthy Adult

Keywords

NAD+ metabolismMarkers of health

Outcome Measures

Primary Outcomes (1)

  • Nicotinamide adenine dinucleotide response in whole blood

    Baseline to Day 14

Secondary Outcomes (8)

  • Nicotinamide adenine dinucleotide metabolite responses

    Baseline to Days 1, 7, 14, and 30

  • Subjective cognitive function visual analog scales

    Baseline to Days 30 and 60

  • Subjective quality of life questionnaire

    Baseline to Days 30 and 60

  • Metabolic health markers

    Baseline to Days 30 and 60

  • Biological age

    Baseline to Days 30 and 60

  • +3 more secondary outcomes

Study Arms (2)

Proprietary nutritional supplement

EXPERIMENTAL

Participants will take the experimental supplement orally, daily.

Dietary Supplement: Proprietary Nutritional Supplement

Placebo supplement

PLACEBO COMPARATOR

Participants will take the placebo supplement orally, daily.

Dietary Supplement: Placebo Supplement

Interventions

Proprietary Nutritional SupplementDIETARY_SUPPLEMENT

1000 mg nicotinamide metabolites and plant extracts, taken orally, daily for 60 days

Proprietary nutritional supplement
Placebo SupplementDIETARY_SUPPLEMENT

1000 mg maltodextrin, taken orally, daily for 60 days

Placebo supplement

Eligibility Criteria

Age45 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females, ≥45 to ≤65 years of age
  • BMI ≥18.5 and \<30.0 kg/m2
  • Ambulatory and currently free of injury or other physical impairment that hinders mobility.
  • Willing to use personal smart phone with operating system (Android version 12.0 or newer; iOS version 16 or newer).
  • Willingness to maintain current skin care regimen and avoid any skin-related medical procedures.
  • Willing to adhere to all study procedures, including lifestyle considerations and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.

You may not qualify if:

  • Is currently following, or planning to be on, a weight loss regimen.
  • Weight loss or gain \>4.5 kg.
  • History of gastrointestinal surgery for weight reducing purposes.
  • History of an eating disorder (e.g., anorexia nervosa or bulimia nervosa, binge eating) at the discretion of the Clinical Investigator.
  • History of neurologic disorder that could produce cognitive deterioration.
  • History of bouts of delirium, confusion, repeated minor head injury or a single injury.
  • History of unconventional sleep patterns or a diagnosed sleep disorder.
  • History of any infective or inflammatory brain disease.
  • Use of tobacco/nicotine products.
  • Use of hemp/marijuana products.
  • Unstable use of any prescription medication.
  • Unstable use (initiation or change in dose) of hormonal contraceptives or therapy.
  • Use of any dietary supplements (orally or infused), other than a conventional once daily multi-vitamin.
  • Use of medication(s) or dietary supplement(s) known to affect absorption.
  • Recent history of or strong potential for alcohol or substance abuse.
  • +10 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Biofortis Clinical Research

Addison, Illinois, 60101, United States

RECRUITING

Study Officials

  • Erin Barrett, PhD

    Shaklee Corporation

    STUDY DIRECTOR

Central Study Contacts

Biofortis Research Clinical Director Biofortis Research Clinical Director

CONTACT

(630) 617-2000biofortisresearch@mxns.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 2, 2026

First Posted

February 24, 2026

Study Start

February 17, 2026

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

June 1, 2026

Last Updated

April 13, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations

US(1)